Updated:
EB5 Life Sciences
EB5 Life Sciences is a San Francisco-based asset manager founded by David Tieh in 2009, raising EB-5 immigrant capital for life-science real estate...
EB5 Life Sciences
David Tieh, a real estate attorney and former U.S. Army officer, launched EB5 Life Sciences in 2009 to connect EB-5 visa investors with life-science infrastructure projects. The firm operates at the intersection of real estate development and healthcare, targeting properties that serve biotech, pharmaceutical, and clinical research tenants — including wet labs, medical office buildings, and drug manufacturing facilities. Wealth origin is not publicly disclosed for the firm's principals. EB5 Life Sciences structures its capital raising through regional centers designated under the federal EB-5 Immigrant Investor Program. The firm oversees the entire process — from identifying projects and securing government approval to placing foreign capital into job-creating ventures. Asset classes include life-science real estate (lab and office space), pharmaceutical manufacturing facilities, and clinical-stage company infrastructure. The firm has cited funded projects such as the BioMed Realty portfolio in San Diego and a life-sciences campus near the University of California, San Francisco — both structured to qualify for EB-5 designation (per public EB-5 project listings, 2020). The firm's total deployment or team size is not publicly available. EB5 Life Sciences operates largely from its San Francisco base. The firm has not disclosed additional offices. No philanthropic or operating-company arms are known. A recent operational marker: in early 2023, the firm continued to list active EB-5 projects in life science real estate bonds and construction loans, per the U.S. Citizenship and Immigration Services regional center pages. EB5 Life Sciences' structural differentiator is its narrow focus on EB-5 visa-driven capital for life-science real estate — a niche that requires both immigration-law expertise and life-science asset knowledge. The firm operates as a project sponsor and regional center operator, not as a traditional real estate fund manager, giving it a regulatory moat tied to federal visa policy.
General information
Firm type
Asset Manager
Year founded
2009
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, California, United States
Principals
David Tieh
Founder & CEO
Angela Tieh
Chief Operating Officer
Sector focus
Frequently asked questions
Who runs investment decisions at EB5 Life Sciences?
David Tieh, the founder and CEO, controls investment strategy. He is a real estate attorney and former U.S. Army officer. Angela Tieh serves as Chief Operating Officer. Both are listed in public SEC filings.
How does EB5 Life Sciences source proprietary deal flow?
The firm identifies life-science real estate projects — labs, medical offices, drug manufacturing plants — that meet EB-5 visa job-creation requirements. They work with developers and tenants in biotech hubs such as San Diego and San Francisco.
Is EB5 Life Sciences structured as a family office or an asset manager?
EB5 Life Sciences is structured as an asset manager, specifically an EB-5 regional center operator and fund sponsor. It does not manage a family's personal wealth but pools capital from foreign investors seeking U.S. visas.
Does EB5 Life Sciences participate in fund commitments or only direct deals?
The firm sponsors specific project-level EB-5 funds rather than open-end pooled vehicles. Each project is structured as a separate limited partnership that qualifies for the EB-5 program.
What investment stages does EB5 Life Sciences typically target?
The firm focuses on development-stage and construction-stage life-science real estate. Projects include new lab buildings, medical office conversions, and pharmaceutical facility expansions.
Which sectors does EB5 Life Sciences explicitly avoid?
The firm avoids non-life-science real estate such as retail, hospitality, residential, and traditional office space. Its mandate is tied to healthcare and biotech infrastructure.
Where does the underlying wealth come from for EB5 Life Sciences investors?
The firm's capital comes from foreign nationals — primarily from China, though EB-5 source countries have diversified — seeking permanent U.S. residency under the EB-5 Immigrant Investor Program. Each investor must prove lawful source of funds.
What is EB5 Life Sciences' known posture on co-investments alongside external GPs?
The firm typically acts as the sole EB-5 capital partner on projects it sponsors. It does not publicly advertise co-investment with traditional real estate fund managers, though some projects may involve joint ventures with developers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: